ArticleJournal of clinical laboratory analysis2026
Improving the Accuracy of Papillary Thyroid Cancer Pathological Evaluation With Digital PCR Detection of the BRAF V600E Mutation.
Article in Journal of clinical laboratory analysis, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
Abstract
backgroundThe BRAF V600E mutation is an important diagnostic factor for papillary thyroid cancer (PTC). Digital PCR (dPCR) is a relatively new technology featured with extremely high sensitivity. This study aims to evaluate the performance of dPCR in detecting BRAF V600E mutations in PTC diagnosis.
methodsA total of 252 thyroid samples were collected in this retrospective diagnostic accuracy study. Diagnosis was made by a pathologist following histopathological guidelines. The BRAF V600E mutation was detected by dPCR and the results were compared with calls from amplification refractory mutation system PCR (ARMS-PCR) tests. Discrepant samples were evaluated again by two pathologists, and the presence of mutations was further confirmed by next generation sequencing (NGS). McNemar's test was used for paired categorical data in statistical analysis.
resultsTest results from dPCR and ARMS-PCR assays were in total agreement for PTC tumor and benign thyroid tissues. However, dPCR assays detected BRAF V600E mutations in four tumor-adjacent normal tissues, one lymph node sample, and two fine-needle aspirate (FNA) samples that were negative in ARMS-PCR tests, all with low frequencies of BRAF V600E mutations. When pathology results were used as the standard, the sensitivity, specificity, positive predictive value (PPV), and negative predictive value (NPV) of dPCR assay were all 100% for tissue and FNA samples, while those of ARMS-PCR assay were 91.2%, 100%, 100%, 96.1%, and 92.9%, 100%, 100%, 95.7% for tissue and FNA samples, respectively.
conclusionsOur data demonstrate that dPCR is a highly valuable tool for PTC molecular pathology.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.